Preventive and/or Therapeutic Agents for Meniere's Disease

a technology for meniere's disease and treatment agents, applied in the field of prevention and/or treatment agents for meniere's disease, can solve the problems of complex attacks subsequently, inconvenient and troublesome patients' daily lives, and the development of hearing loss from the medium to the advanced stage, and achieve the effect of effective prevention and/or treatment agents

Inactive Publication Date: 2007-10-25
ONO PHARMA CO LTD +1
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0063] The present invention can provide the effective pr

Problems solved by technology

The attacks are often complicated subsequently by autonomic nerve symptoms, such as nausea, vomiting, shoulder stiffness, headache and the like.
Meniere's disease undergoes exacerbation in the course of recurrence of the attacks over a prolonged period of time, and when the condition of disease or the pathology progresses to the terminal stage, among others, hearing impairment gets worse to such a profound degree as may cause inconvenience and troubles to patients' daily lives, resulting eventually in development into the medium to advanced degree of hearing loss.
However, it is known that isosorbide is not

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preventive and/or Therapeutic Agents for Meniere's Disease

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0065] Pranlukast hydrate (trade name: onon capsule) was administered to 19 patients afflicted with Meniere's disease at a daily dose of 450 mg (two capsules each containing 112.5 mg individually after breakfast and after dinner) for the period of not less than three weeks (up to 24 weeks max.) to test and determine the efficacy. The overall efficacy (therapeutic) assessment was performed mainly on the basis of the results of nystagmus and hearing tests, while also taking into consideration the subjective symptoms (rotary vertigo, tinnitus, a feeling of fullness in ear, hearing rimpairment, etc.) and the extent or degree of hearing impairment (average hearing, method of quartering). In consequence of this, the efficacy was recognized and determined in 17(89.5%) out of 19 patients afflicted with Meniere's disease. The breakdown of efficacy indicated that the drug agent elicites the efficacy in 15 out of 19 patients complaining of the subjective symptoms (78.9%) and in 15 out of 19 pa...

example 2

[0067] Pranlukast hydrate (trade name: Onon capsule) was administered to the patients suffering from acute low-tone sensorineural hearing loss concurrently with a feeling of fullness in the left ear at a daily dose of 450 mg (two capsules each containing 112. 5 mg given individually after breakfast and dinner) for two months to investigate into the efficacy against hearing impairment, the major complaint. In connection to the above test, it is to be noted that selection of patients was performed in accordance with a draft of the Criteria for Diagnosis proposed by Study Group for Acute Severe Hearing Loss of the Ministry of Health, Labor and Welfare of Japan (refer to Audiology Japan., 45, 161-166 (2002)).

[0068] The efficacy evaluation was performed on the basis of the Criteria for Efficacy Evaluation drawn up by Study Group for Acute Severe Hearing Loss of the Ministry of Health, Labor and Welfare of Japan (refer to Audiology Japan., 45, 161-166 (2002)); the cases, whose hearing le...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Massaaaaaaaaaa
Massaaaaaaaaaa
Massaaaaaaaaaa
Login to view more

Abstract

The present invention relates to preventive and/or therapeutic agents for Meniere's disease, which comprise a leukotriene antagonist (such as pranlukast hydrate) as an active ingredient. Leukotriene antagonists (such as pranlukast hydrate) are effective in ameliorating various symptoms, such as hearing impairment, tinnitus, a feeling of fullness in the ear and vertigo, thus being useful as a preventive and/or therapeutic agent for Meniere's disease.

Description

TECHNICAL FIELD [0001] The present invention is concerned with preventive and / or therapeutic agents for Meniere's disease which comprise a leukotriene antagonist as an active ingredient. BACKGROUND ART [0002] Meniere's disease is a disease characterized by the cardinal symptom of recurrent attacks of vertigo, which attacks are associated with the cochlear symptoms, such as hearing impairment, tinnitus and a feeling of fullness in the ear, etc. [0003] The symptoms of vertigo occur in a wide variety of different conditions ranging from severe rotary vertigo to swaying or shaking immobile vertigo: one of such symptoms disappears within several minutes or continues for some hours, whereas the other involves repetition of ameliorated and aggravated dizziness over the extended period of time as long as several days. On the other hand, also known is cochlear Meniere's disease, which is associated with repeated appearance or manifestation and disappearance of hearing impairment, tinnitus an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/4035A61K31/41A61P27/16
CPCA61K31/4035A61K31/41A61K45/06C07D405/04A61K2300/00A61P27/16
Inventor KAWATA, KAZUYANAKAO, KENZOMIZUSHIMA, KENMATSUOKA, SHOZO
Owner ONO PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap